Heterologous, autologous cell therapy could treat hemophilia B

A study published in Cell Reports from researchers at Salk Institute for Biological Studies suggests that heterologous and autologous cell therapy could help treat hemophilia B.

Hemophilia B is characterized by a systemic lack of clotting Factor IX. Recombinant human Factor IX supplements used to treat the disease require frequent IV administration and become less effective over time...